TL;DR
This study reveals that the receptor tyrosine kinase AXL, specifically its phosphorylated (active) form, plays a crucial protective role against liver ischemia-reperfusion (I/R) injury, particularly in the context of alcohol-associated liver disease (ALD). By activating AXL, researchers were able to significantly reduce ER stress and mitochondria-mediated apoptosis, offering a promising therapeutic target for improving outcomes in liver transplantation and surgery.
What Problem Does This Paper Address?
Hepatic ischemia-reperfusion (I/R) injury is a significant clinical challenge, often leading to poor outcomes in liver transplantation and partial hepatectomy. This problem is exacerbated in patients with alcohol-associated liver disease (ALD), where the liver is already compromised by steatosis. The underlying mechanisms of I/R injury, particularly the role of hepatocyte death via apoptosis triggered by endoplasmic reticulum (ER) stress and mitochondrial dysfunction, are complex and not fully understood. Existing treatments are limited, and there's a pressing need to identify novel therapeutic targets to improve the utilization of marginal liver grafts, such as those from donors with ALD. This paper aims to elucidate the role of AXL, a receptor tyrosine kinase, in hepatic I/R injury and its potential as a therapeutic target, especially in ALD.
Methods
The researchers employed a multi-pronged approach:
- Human Samples: Liver biopsies from liver transplant donors and control individuals were analyzed to assess AXL and phosphorylated AXL (p-AXL) expression.
- Animal Models:
- Hepatic I/R Model: Standard surgical models of liver ischemia and reperfusion were established in mice.
- ALD Model: A chronic-plus-binge ethanol feeding model was used to induce alcoholic fatty liver disease in mice.
- In Vitro Models: Primary hepatocytes were isolated and subjected to oxygen-glucose deprivation/reoxygenation (OGD/R) to mimic I/R injury at the cellular level.
- Pharmacological Interventions:
- Recombinant mouse Gas6 (rmGas6) was used to activate AXL.
- R428, a specific AXL inhibitor, was used to block AXL activity.
- TUDCA, a known ER stress inhibitor, was used as a positive control.
- Molecular and Cellular Assays:
- Western Blotting: To quantify protein expression levels of AXL, p-AXL, and various markers of ER stress (BiP, CHOP, IRE1, PERK, ATF4, XBP1s) and apoptosis (cleaved Caspase-3, -9, -12, Bax, Bcl-2).
- Immunohistochemistry (IHC): To visualize the spatial distribution of p-AXL and CHOP in liver tissues.
- Transmission Electron Microscopy (TEM): To examine the ultrastructural changes in ER and mitochondria.
- TUNEL Assay: To detect apoptotic cells.
- Flow Cytometry: To quantify hepatocyte apoptosis.
- Liver Function Tests: Measurement of serum ALT and AST levels as indicators of liver damage.
- Oil Red O Staining: To assess lipid accumulation in the liver.
Datasets
Not discussed in the paper. The study primarily relies on experimental data generated from human samples and animal/cellular models.
Key Insights and Ideas
- AXL's Dual Nature in I/R: While total AXL expression increases during I/R, its active, phosphorylated form (p-AXL) actually decreases. This suggests that simply having more AXL isn't enough; its activation is critical.
- Gas6 as an AXL Activator: Exogenous administration of Gas6, the natural ligand for AXL, effectively activates AXL, leading to improved liver function and reduced injury.
- AXL's Protective Mechanism: Activated AXL appears to protect the liver by directly targeting ER stress and mitochondria-associated apoptosis. It achieves this by inhibiting key pathways within the Unfolded Protein Response (UPR), specifically the IRE1 and PERK branches.
- ALD Exacerbates I/R Injury and Dampens AXL: In ALD models, p-AXL levels are even lower, and the liver is more susceptible to I/R injury, highlighting the critical role of AXL in this disease context.
- Soluble AXL (sAXL) as a Biomarker: The study identified elevated sAXL in the serum of I/R mice, suggesting it could be a potential biomarker for liver injury and offering a new avenue for therapeutic intervention by targeting its production.
Key Results
- Human and Mouse I/R: In both human donor livers and mouse models of I/R, total AXL was upregulated, while p-AXL was downregulated.
- Gas6 Treatment Benefits: Pretreatment with Gas6 in mice significantly reduced liver damage (lower ALT/AST levels, reduced necrotic area), alleviated ER stress markers (BiP, CHOP), and decreased apoptosis (cleaved Caspase-3). TEM confirmed restoration of ER and mitochondrial ultrastructure.
- AXL Inhibition Worsens Injury: Using the AXL inhibitor R428 exacerbated I/R injury, increasing liver damage and ER stress markers.
- ALD Model Susceptibility: ALD mice showed lower p-AXL levels and were more prone to severe liver damage and apoptosis after I/R compared to control mice.
- In Vitro Confirmation: Similar protective effects of rmGas6 were observed in primary hepatocytes subjected to OGD/R, confirming AXL's role at the cellular level.
- ER Stress Pathway Inhibition: Activated AXL significantly reversed the upregulation of ER stress markers like p-IRE1, XBP1s, p-PERK, and ATF4 during I/R.
- Mitochondrial Apoptosis Inhibition: Activated AXL reduced pro-apoptotic proteins (Bax, cleaved Caspase-9) and increased anti-apoptotic protein (Bcl-2) expression.
Limitations and Future Work
- Soluble AXL (sAXL) Mechanism: While sAXL was identified as elevated and potentially competitive with Gas6, its precise role and how to therapeutically target its production or activity require further investigation.
- ALD Complexity: The study used a chronic-plus-binge model for ALD. Further research could explore the nuances of different stages and severities of ALD and their impact on AXL signaling.
- Translational Potential: While promising, further preclinical and clinical studies are needed to validate AXL activation as a safe and effective therapeutic strategy for human liver I/R injury, especially in the context of marginal donors.
- Specific Downstream Targets: While the study implicates IRE1 and PERK pathways, a more detailed dissection of downstream targets and signaling cascades modulated by activated AXL could provide deeper mechanistic insights.
- Marginal Donor Utilization: The paper strongly suggests AXL targeting as a strategy for utilizing marginal liver donors with steatosis. Future work could focus on developing and testing specific AXL-activating therapies for this purpose.
Summary updated